AVITA Medical (ASX:AVH): Wound Care Portfolio and Revenue Progress

Aditi Sarkar

30 October 2026 08:16 PM AEDT

AVITA Medical (ASX:AVH): Wound Care Portfolio and Revenue Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AVITA Medical operates an acute wound care business built around technologies for treating burns and trauma wounds.
Its second-quarter 2026 revenue reached $21.7 million, an increase of 18% year on year.
The company increased its full-year 2026 revenue guidance to $86 million–$89 million.
Commercial activities include the RECELL platform alongside PermeaDerm and Cohealyx.

AVITA Medical, Inc. develops and commercialises technologies used in acute wound care, including the RECELL platform for burns and trauma wounds Its published second-quarter 2026 results provide a view of product revenue, cash expenditure and the company’s commercial priorities ahead of the next reporting update.

Commercial Portfolio and Recent Reporting

For the quarter ended 30 June 2026, AVITA Medical (ASX:AVH) reported net revenue of $21.7 million, rising 18% year on year and 13% from the preceding quarter. The company attributed the increase to its commercial portfolio, led by RECELL and supported by adoption of Cohealyx and PermeaDerm. This breakdown is relevant because the company now reports activity across several wound care products rather than a single offering.

Operating Costs and Funding Position

Gross profit margin for the second quarter was 81.9%, compared with a margin 70 basis points lower in the corresponding period. Operating expenses were $24.6 million, representing a 6% year-on-year reduction. The combination of revenue growth and expense control is visible in the quarterly financial measures, although the business continued to report a net loss.

AVITA Medical (ASX:AVH) reported a quarterly net loss of $7.7 million, compared with $9.9 million in the comparable period. Net cash use was approximately $3.2 million against $9.9 million in the first quarter of 2026. At 30 June, cash, cash equivalents and marketable securities totalled approximately $11.1 million. These figures distinguish accounting performance from movements in available cash.

Product Development and Guidance

Within its portfolio, RECELL recorded second-quarter revenue of $18.5 million, approximately 11% above the preceding quarter. Management identified RECELL GO mini adoption as one component of sequential activity. A separate August 2026 announcement reported positive study findings for PermeaDerm, adding clinical information about another product in the portfolio.

AVITA Medical (ASX:AVH) raised full-year 2026 net revenue guidance from $80 million–$85 million to $86 million–$89 million in August. It also communicated an expectation of reaching cash-flow breakeven in the fourth quarter of 2026. Both were company expectations at the announcement date, not outcomes already achieved. The company scheduled release of its third-quarter 2026 financial results for November.

The company has also distinguished reimbursement policy proposals from implemented payment decisions in its financial communications. In July 2026, US authorities published proposed 2027 payment changes covering certain RECELL procedures. Such proposals describe a regulatory process rather than an established new payment schedule. For AVITA Medical (ASX:AVH), the distinction is significant to describing the commercial environment without treating proposed rules as final.

The quarter also illustrated how different financial indicators describe different parts of the same business. Revenue measures product and service activity recorded in the period; gross margin measures revenue remaining after the costs classified as cost of sales; and operating expenses capture additional expenditure. Cash use, meanwhile, shows cash movements rather than the accounting net loss. The company published all of these measures together, allowing the June-quarter performance to be assessed in context without reducing it to one percentage. The August guidance update should likewise be kept separate from the actual figures reported for the three months ended June.

Key Insights

AVITA Medical (ASX:AVH) enters its next reporting period with second-quarter revenue growth, lower cash use and a wider acute wound care portfolio documented in official releases. Its updated guidance and announced reporting timetable provide the principal near-term context. The difference between reported revenue, net losses and cash movements remains important when interpreting its operating position.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.